Ticker

No recent analyst price targets found for TIVC.

Latest News for TIVC

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue Base SAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC…

PRNewsWire • Apr 23, 2026
Tivic Health Systems (NASDAQ:TIVC) Director Sheryle Bolton Purchases 10,000 Shares of Stock

Tivic Health Systems, Inc. (NASDAQ: TIVC - Get Free Report) Director Sheryle Bolton acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.04 per share, with a total value of $10,400.00. Following the transaction, the director owned 10,000 shares in the

Defense World • Apr 21, 2026
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Department of War's Tech Watch program on May 7, 2026. The Tech Watch initiative identifies emerging technologies with high-value defense and dual-use applications.

PRNewsWire • Apr 15, 2026
Reviewing Omnicell (NASDAQ:OMCL) & Tivic Health Systems (NASDAQ:TIVC)

Tivic Health Systems (NASDAQ: TIVC - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Tivic

Defense World • Apr 6, 2026
Tivic Health Systems Touts Entolimod Phase 3 ARS Path, Eyes BLA in 2027-2028 at Conference

Tivic Health Systems (NASDAQ: TIVC) outlined its strategy to advance what it described as late-stage, "highly de-risked" biopharma assets over the next 12 to 24 months, with a primary focus on Entolimod, a Toll-like receptor 5 (TLR5) agonist. Speaking during the event, company executive Michael said the company is focused on immune therapies intended to improve

Defense World • Apr 3, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for TIVC.

No House trades found for TIVC.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top